SC Adult plaque psoriasis 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Based on clinical response, maintenance dose of 300 mg every 2 wk may provide additional benefit for patients weighing ≥90 kg. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg.
Paed plaque psoriasis Recommended dose is based on body wt w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.
Patient weighing ≥50 kg 150 mg, may be increased to 300 mg,
25-<50 kg 75 mg,
<25 kg 75 mg.
Psoriatic arthritis Patient w/ concomitant moderate to severe plaque psoriasis 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Based on clinical response, maintenance dose of 300 mg every 2 wk may provide additional benefit for patients weighing ≥90 kg. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg.
Anti-TNFα inadequate responder 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg.
Other patient 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing, can be increased to 300 mg based on clinical response.
Ankylosing spondylitis 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing, can be increased to 300 mg based on clinical response. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg.
Non-radiographic axial spondyloarthritis 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.